Linked Life Data

15831492

Source:http://linkedlifedata.com/resource/pubmed/id/15831492

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15831492rdf:typepubmed:Citationlld:pubmed
pubmed-article:15831492lifeskim:mentionsumls-concept:C0014597lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C1709385lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C1335191lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C2611812lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C2613365lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:15831492lifeskim:mentionsumls-concept:C1517945lld:lifeskim
pubmed-article:15831492pubmed:issue24lld:pubmed
pubmed-article:15831492pubmed:dateCreated2005-6-13lld:pubmed
pubmed-article:15831492pubmed:abstractTextThe apoptosis-promoting protein Par-4 has been shown to be down-regulated in Ras-transformed NIH 3T3 fibroblasts through the Raf/MEK/ERK MAPK pathway. Because mutations of the ras gene are most often found in tumors of epithelial origin, we explored the signaling pathways utilized by oncogenic Ras to down-regulate Par-4 in RIE-1 and rat ovarian surface epithelial (ROSE) cells. We determined that constitutive activation of the Raf, phosphatidylinositol 3-kinase, or Ral guanine nucleotide exchange factor effector pathway alone was not sufficient to down-regulate Par-4 in RIE-1 or ROSE cells. However, treatment of Ras-transformed RIE-1 or ROSE cells with the MEK inhibitors U0126 and PD98059 increased Par-4 protein expression. Thus, although oncogenic Ras utilizes the Raf/MEK/ERK pathway to down-regulate Par-4 in both fibroblasts and epithelial cells, Ras activation of an additional signaling pathway(s) is required to achieve the same outcome in epithelial cells. Methylation-specific PCR showed that the par-4 promoter is methylated in Ras-transformed cells through a MEK-dependent pathway and that treatment with the DNA methyltransferase inhibitor azadeoxycytidine restored Par-4 mRNA transcript and protein levels, suggesting that the mechanism for Ras-mediated down-regulation of Par-4 is by promoter methylation. Support for this possibility is provided by our observation that Ras transformation was associated with up-regulation of Dnmt1 and Dnmt3 DNA methyltransferase expression. Finally, ectopic Par-4 expression significantly reduced Ras-mediated growth in soft agar, but not morphological transformation, highlighting the importance of Par-4 down-regulation in specific aspects of Ras-mediated transformation of epithelial cells.lld:pubmed
pubmed-article:15831492pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:languageenglld:pubmed
pubmed-article:15831492pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:citationSubsetIMlld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15831492pubmed:statusMEDLINElld:pubmed
pubmed-article:15831492pubmed:monthJunlld:pubmed
pubmed-article:15831492pubmed:issn0021-9258lld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:KoposovR ARAlld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:DerChanning...lld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:ShieldsJaniel...lld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:PruittKevinKlld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:RangnekarVive...lld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:RojasRafael...lld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:FrantzKarenKlld:pubmed
pubmed-article:15831492pubmed:authorpubmed-author:Muniz-MedinaV...lld:pubmed
pubmed-article:15831492pubmed:issnTypePrintlld:pubmed
pubmed-article:15831492pubmed:day17lld:pubmed
pubmed-article:15831492pubmed:volume280lld:pubmed
pubmed-article:15831492pubmed:ownerNLMlld:pubmed
pubmed-article:15831492pubmed:authorsCompleteYlld:pubmed
pubmed-article:15831492pubmed:pagination23363-70lld:pubmed
pubmed-article:15831492pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:meshHeadingpubmed-meshheading:15831492...lld:pubmed
pubmed-article:15831492pubmed:year2005lld:pubmed
pubmed-article:15831492pubmed:articleTitleRas-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells.lld:pubmed
pubmed-article:15831492pubmed:affiliationDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599-7295, USA.lld:pubmed
pubmed-article:15831492pubmed:publicationTypeJournal Articlelld:pubmed
More...